Keith Alexander - ExpreS2ion Biotech Chief Officer
| EXPRS2 Stock | SEK 18.68 0.06 0.32% |
Insider
Keith Alexander is Chief Officer of ExpreS2ion Biotech Holding
| Phone | 45 22 22 10 19 |
| Web | https://www.expres2ionbio.com |
ExpreS2ion Biotech Management Efficiency
The company has return on total asset (ROA) of (0.5513) % which means that it has lost $0.5513 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9735) %, meaning that it generated substantial loss on money invested by shareholders. ExpreS2ion Biotech's management efficiency ratios could be used to measure how well ExpreS2ion Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Johanna Flting | BioArctic AB | 51 | |
| Jan Mattsson | BioArctic AB | 63 | |
| Sren MSc | Hansa Biopharma AB | 58 | |
| Gunilla Andersson | BioArctic AB | 62 | |
| Oskar Bosson | BioArctic AB | 47 | |
| Nina Ivers | Xbrane Biopharma AB | 53 | |
| Maria Edebrink | Xbrane Biopharma AB | 54 | |
| Frida Lekander | BioArctic AB | N/A | |
| Anette Lindqvist | Xbrane Biopharma AB | 57 | |
| David Vikstrm | Xbrane Biopharma AB | 46 | |
| Pr Gellerfors | BioArctic AB | 76 | |
| Harald Borgeke | BioArctic AB | N/A | |
| Martin mark | Xbrane Biopharma AB | 43 | |
| Pr Lannfelt | BioArctic AB | 74 | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Erik Domines | Xbrane Biopharma AB | 59 | |
| Gunilla Osswald | BioArctic AB | 62 | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| Christer Mller | BioArctic AB | 64 | |
| Katja Margell | Hansa Biopharma AB | N/A | |
Management Performance
| Return On Equity | -0.97 | |||
| Return On Asset | -0.55 |
ExpreS2ion Biotech Leadership Team
Elected by the shareholders, the ExpreS2ion Biotech's board of directors comprises two types of representatives: ExpreS2ion Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ExpreS2ion. The board's role is to monitor ExpreS2ion Biotech's management team and ensure that shareholders' interests are well served. ExpreS2ion Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ExpreS2ion Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Keith Alexander, Chief Officer | ||
| Lars Petersen, Medical Oncology | ||
| Mette Thorn, VP Devel | ||
| Bent MSc, Chief Officer | ||
| Mattis Ranthe, Chief Officer | ||
| Max Sogaard, Dev Research |
ExpreS2ion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ExpreS2ion Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.97 | |||
| Return On Asset | -0.55 | |||
| Operating Margin | (20.75) % | |||
| Current Valuation | 361.15 M | |||
| Shares Outstanding | 37.15 M | |||
| Shares Owned By Institutions | 1.75 % | |||
| Price To Book | 3.42 X | |||
| Price To Sales | 55.94 X | |||
| Revenue | 12.23 M | |||
| Gross Profit | 1.07 M |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in ExpreS2ion Stock
ExpreS2ion Biotech financial ratios help investors to determine whether ExpreS2ion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ExpreS2ion with respect to the benefits of owning ExpreS2ion Biotech security.